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Renal hypertrophy and deposition of extracellular matrix
proteins are consistent findings in diabetic nephropathy and
these processes can be halted or reversed by euglycemic
control. Using DNA microarray analysis of glomerular RNA
from control and diabetic rats we found that the expression
levels of insulin-like growth factor 1 receptor (IGF-1R) were
increased while those of suppressor of cytokine signaling
2 (SOCS2) and STAT5 were decreased. All of these changes
were normalized by islet cell transplantation. Overexpression
of SOCS2 in rat mesangial cells inhibited IGF-1-induced
activation of extracellular signal-regulated kinase, which
subsequently reduced type IV collagen and DNA synthesis,
an effect due to interaction of SOCS2 with IGF-1R. Inhibition
of SOCS2 overexpression by small interfering RNA
suppressed IGF-1R-mediated actions by preventing
phosphorylation of tyrosine 317 in the p66Shc adaptor
protein; however, overexpression of either SOCS1 or SOCS3
did not affect IGF-1R signaling. Insulin directly increased
STAT5 and SOCS2 expression in mesangial cells. This study
shows that insulin can inhibit the mitogenic action of IGF-1 in
mesangial cells by regulating STAT5/SOCS2 expression.
Insulin deficiency may contribute to the mesangial expansion
found in diabetes through reduced STAT5/SOCS2 expression.
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published online 13 August 2008
KEYWORDS: diabetes; insulin; SOCS2; STAT; signaling; nephropathy
Diabetic nephropathy is a leading cause of end-stage renal
failure,1 and the initial phases are characterized by the
activation and proliferation of glomerular and renal tubular
cells, resulting in enlarged kidneys. These pathological
changes involve renal cellular proliferation and increased
expression of extracellular matrix (ECM) proteins.
A combination of nephromegaly and mesangial expansion
leads to glomerulosclerosis and tubulointerstitial fibrosis,
contributing to renal failure.2,3 Many growth factors,
cytokines and vasoactive hormones can affect mesangial cell
proliferation and synthesis of ECM proteins, and abnormal
regulation of the expression of these molecules has been
demonstrated in the early stages of diabetic nephropathy.4
Amongst these, growth hormone and insulin-like growth
factor-1 (IGF-1) have been implicated due to their mitogenic
actions on glomerular and tubular cells. However, the
potential mechanisms used by these growth factors to induce
the renal phenotype are not clear, as these growth factors do
not display consistent elevated levels of expression in renal
tissues.5 Thus, the exact mechanism by which hyperglycemia
or diabetes can increase IGF-1’s action on glomerular cells
and upregulate the expression of extracellular proteins in
glomerular tissues is unclear.
We have thus used a DNA microarray to identify changes
in the expression of various genes in the glomeruli from
control rats, untreated diabetic rats and diabetic rats
receiving islet cell transplantation (ICT). ICT was chosen to
be the treatment because it is the most effective method to
restore normal physiology in the diabetic state and has been
reported to partially reverse the glomerular pathology in
diabetic patients.6 From the panel of changes in gene
expression that can be induced by diabetes and subsequently
normalized by ICT, we have identified that the mRNA
expression of IGF-1R and suppressor of cytokine signaling 2
(SOCS2) were consistently altered. Increased expression of
IGF-1R has been reported in diabetes and can induce ECM
protein synthesis in mesangial cells. However, the plasma
levels and the expression levels of IGF-1 in the renal
parenchyma may be decreased in diabetes with poor glycemic
control.7 However, it was the novel finding that the SOCS2
mRNA expression was also decreased that suggested a
potential regulatory mechanism by which the action of
IGF-1 can be enhanced to cause glomerular abnormalities.
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SOCS2 is a member of SOCS family, a group of related
proteins implicated in the negative regulation of cytokine
action through inhibition of the Janus kinase/signal transdu-
cers and activators of transcription (STAT) signal-transduc-
tion pathway.8 Several SOCS isoforms have been reported to
alter tyrosine kinase activity of growth factor receptors.9–12
SOCS2 may have a negative regulatory role in IGF-1 signaling
because it has been reported to associate with IGF-1R and
decrease its biological actions. SOCS2-deficient mice exhibit
accelerated postnatal growth resulting in gigantism.13,14
However, there have been no reports about metabolic
regulation of SOCS2 on IGF-1 signaling through IGF-1R in
pathological states such as diabetic nephropathy. In addition,
the possibility of insulin’s role in the regulation of SOCS2 and
inhibition of the mitogenic effects of IGF-1 has also not been
shown.
In this study, we have identified a decrease in the
expression of SOCS2 in both renal glomeruli commonly
involved in diabetic microvascular complications. Further-
more, we have characterized in detail the interaction between
SOCS2 and IGF-1R as well as the potential cellular signaling
pathways that these two molecules utilize to the expression of
ECM proteins and DNA synthesis in mesangial cells.
RESULTS
Physiological phenotypes of control, diabetic, and islet cell
transplant-treated diabetic rats
Three groups of rats were used for this study including
nondiabetic control rats, diabetic rats, and diabetic rats that
received ICT 4 weeks after the onset of diabetes.15 All rats
were sacrificed 8 weeks after the onset of diabetes for analysis.
Diabetic rats displayed hyperglycemia (339±88 mg/100 ml
versus 95±6 mg/100 ml for control rats) that was completely
normalized by ICT (105±9 mg/100 ml; Supplementary
Figure 1). Rats with 8 weeks of diabetes have increased
kidney/body weight (100 gram) ratio (0.99±0.12 versus
0.81±0.08 of controls, Po0.05, n¼ 20) that was rectified
following euglycemic control by 4 weeks of ICT (0.84±0.07,
Po0.05 versus diabetic group; Figure 1a). The presence of
nephromegaly is associated with alterations of kidney
function such as increased glomerular filtration rate (GFR;
3.15±0.74 ml/min in diabetic rats versus 1.75±0.42 ml/min
in control rats, Po0.05) and calculated filtration fraction
(0.34±0.07 in diabetic rats versus 0.22±0.05 in control rats,
Po0.05; Figure 1b–d). These mimic the abnormal renal
functions in diabetic patients with poor glycemic control.16
All of these changes were reversed after 4 weeks of euglycemic
controls by ICT (GFR of 2.29±0.64 ml/min and filtration
fraction of 0.22±0.06; Figure 1b–d), suggesting that they are
specific to diabetes.
Expression profiling of renal glomeruli
Following the demonstration of renal dysfunction and
enlargement in this diabetic rat model, we profiled the gene
expression pattern in the glomerular tissues from the three
groups of rats.17 Using a fivefold change as the cutoff
criterion, 148 genes were identified to have increased
expression in diabetes whereas the mRNA 223 other genes
was downregulated. From these genes, the expressions of 32
upregulated and 69 downregulated genes were normalized by
ICT (Supplementary database). Among the genes with
altered expressions, SOCS2 were selected for further
investigation because it had not been associated with diabetic
renal complications or any other vascular pathologies, and it
is associated with the action of IGF-1 and cellular growth
which could be important for renal hypertrophy and
mesangial expansion in early diabetic nephropathy.
The results of the DNA microarray analysis also identified
a consistent 1.5-fold increase of IGF-1R in the renal
glomeruli of STZ rats, which remained elevated with ICT
treatment (Figure 2a). The mRNA expression of IGF-1 was
not altered by diabetes. The changes in IGF-1R and SOCS2
mRNA expression detected by microarray analysis were
confirmed by reverse transcription (RT)–PCR using total
RNA from glomeruli of all three groups of rats (Figure 2b).
The protein expressions of IGF-1R and SOCS2 in the
glomeruli of three groups were confirmed by immunoblot
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Figure 1 | Effects of islet cell transplantation (ICT) on the
physiological parameters in diabetic rats (STZ). (a) Kidney
weight/100 g body weight was increased in STZ-treated group
and can be reversed by ICT (n¼ 20, mean±s.d., *Po0.05 as
compared to control (CTR) rats). (b) Glomerular filtration rate
(GFR) was significantly increased in rats with diabetes for 4 and
8 weeks (Po0.05, n¼ 5–7 rats per group), respectively, that was
normalized by ICT. (c) Renal plasma flow (RPF). (d). Calculated
filtration fraction (FF) was increased in rats with diabetes for 4 or
8 weeks (Po0.05, n¼ 5–7 rats per group), respectively, and was
normalized by ICT.
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analysis. IGF-1Rb protein expression was elevated in
glomeruli of STZ by 48% (n¼ 11, Po0.05) that was
completely normalized to basal level after 4 weeks of ICT
(Figure 2c). Similarly, SOCS2 protein expression in the
glomeruli of STZ rats was decreased by 30% (Po0.05, n¼ 4;
Figure 2d), in parallel to changes in mRNA levels as shown by
microarray study. Islet cell transplant also revised the
decrease in SOCS2 protein expression (Supplementary Figure
2). Immunohistochemical studies were performed and
presence of SOCS2 was observed in the glomeruli (data not
shown). The possible expression of SOCS2 by the mesangial
cells was further studied. The effects of insulin and
hyperglycemia on the expressions of IGF-1Rb and SOCS2
protein levels in cultured rat mesangial cells were also
determined (Figure 2e). Increasing extracellular glucose
concentrations from 5.6 to 27.8 mM enhanced IGF-1R protein
expression by 69% (n¼ 6, Po0.05). Addition of 100 nM of
insulin for 3 days in media containing 27.8 mM glucose
decreased IGF-1R to that of 5.6 mM. Unlike IGF-1R, the
expression of SOCS2 protein was increased significantly by
co-incubation with 100 nM of insulin and 27.8 mM of glucose
in mesangial cells. Elevating glucose levels alone from 5.6 to
27.8 mM did not have any effect on SOCS2 protein expression
in the mesangial cells.
The effect of diabetes on decreasing SOCS2 expression in
the renal glomeruli appears to be specific because the protein
expression of both SOCS1 and SOCS3 was not altered in
diabetes (data not shown).
Effects of SOCS2 on IGF-1-induced DNA synthesis and
type IV collagen expression in mesangial cells
The proliferation of mesangial cells and the excessive
accumulation of ECM proteins such as type IV collagen
contribute to glomerular or mesangial expansion and
nephromegaly.4 We tested the possibility that changes in
SOCS2 expression can alter IGF-1’s biological actions. SOCS2
was overexpressed using adenoviral vectors, and its effects on
IGF-1-induced collagen production and cell proliferation were
studied. Infection of cultured mesangial cells by adenoviral
vector containing SOCS2 (multiplicity of infection of 100–400)
resulted in a dose-dependent increase in SOCS2 protein
expression (Figure 3a). To differentiate this induction is due to
exogenously expressed SOCS2 rather than upregulation of
endogenous SOCS2, recombinant SOCS2 protein was fused to
a hemagglutinin (HA) tag which subsequently demonstrated
that the increase in SOCS2 was derived from adenoviral vector
infection (Figure 3a). Infection with adenoviral vector
containing green fluorescent protein (GFP) was used as a
control. As shown in Figure 3, IGF-1 (50 nM) significantly
increased the 5-bromo-2-deoxyuridine (BrdU) incorporation,
a surrogate marker for DNA synthesis in mesangial cells by
approximately twofold (n¼ 6, Po0.05). The overexpression of
SOCS2 protein reduced IGF-1’s action on BrdU incorporation
by 30% (n¼ 6, Po0.05 versus GFPþ IGF-1; Figure 3b).
Induction of SOCS2 protein in mesangial cells by adenoviral
infection did not change DNA synthesis in mesangial cells
without the addition of IGF-1 (Figure 3b).
IGF1R SOCS2
SOCS2
CT
R
ST
Z ICT CT
R
ST
Z ICT
CT
R
ST
Z
ICT3
2
1
0
m
R
N
A 
(fo
ld 
ch
an
ge
)
600 GAPDH
GAPDH600
300
200
IGF-1R
IGF1 R
IGF1 R
Actin
Ctl DM+InsDM
*
*
*
*
*
Fo
ld
 c
ha
ng
e 3.53.0
2.5
2.0
1.0
1.5
0.5
0.0
Ctl DM Ins
Ctl
Ctl
DM
DM
SOCS2
SO
CS
2/
Ac
tin
(a.
u.)
Actin
SOCS2
Actin
1.5
1.0
0.5
0.0
Glucose 5.6 mM 27.8 mM
Insulin (100 nM) – –
– –
+
+
IGF-1Rβ
2
1
0
2
1
0
IG
F1
Rβ
 
e
xp
re
ss
io
n
(fo
ld 
ch
an
ge
)
SO
CS
2 
ex
pr
es
sio
n
 
(fo
ld 
ch
an
ge
)
Insulin
5.6 mM 27.8 mM
a
d e
b c
Figure 2 | Diabetes altered the glomerular expression of IGF-1R and SOCS2 in vivo and in vitro. (a) Affymatrix analysis revealed
increased IGF-1R expression in glomeruli from diabetic rats (STZ) and diabetic rats treated with ICT. By contrast, SOCS2 expression was
reduced in diabetic glomerular tissues but was normalized in rats treated with ICT. (b) RT–PCR confirmed the mRNA expression changes as
detected by microarray analysis. (c) Immunoblotting using antibodies against IGF-1R and SOCS2 confirmed the changes in the expression of
IGF-1Rb and SOCS2 in diabetic glomerular tissues (n¼ 11, mean±s.d., *Po0.05). (d) Expression of SOCS2 protein in glomerular tissues
isolated from rats with (DM) or without (Ctl) 8 weeks of strepozotocine-induced diabetes (n¼ 4, Po0.05). (e). Protein expression of IGF-1R
and SOCS2 in isolated mesangial cells cultured in media containing either 5.5 or 27.8 mM glucose with or without 100 nM insulin (n¼ 3–6,
mean±s.d., *Po0.05).
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Furthermore, IGF-1 increased the mRNA expression of
collagen IV in cultured mesangial cells by 1.3-fold as detected
by northern blotting following the normalization to the
expression of housekeeping gene 36B4 (n¼ 4, Po0.05 versus
unstimulated control cells; Figure 3c). Overexpression of
SOCS2 totally suppressed IGF-1’s induction on collagen IV
mRNA expression (Figure 3c).
The inhibitory effect of SOCS2 on IGF-1’s action is
apparently isoform specific because overexpressions of
SOCS1 and SOCS3, respectively, to a similar level in
mesangial cells, did not block IGF-1-induced BrdU incor-
poration in mesangial cells (data not shown).
Effects of gene silencing of endogenous SOCS2 on IGF-1’s
action
As overexpression of SOCS2 suppressed the effects of IGF-1
on mesangial cell proliferation and ECM protein production,
we further investigated whether downregulation of SOCS2,
similar to that in diabetic glomerular tissues, can enhance
IGF-1’s action. RNAi that selectively targets to SOCS2 but
not other isoforms was designed. As shown in Figure 4,
transfection with SOCS2 RNAi decreased the protein
expression of exogenously overexpressed SOCS2 by 80%
whereas the expression of SOCS1 and three isoforms were
not changed (Figure 4a). Downregulation of SOCS2
increased IGF-1-induced extracellular signal-regulated kinase
(ERK)1/2 phosphorylation by 40%. Interestingly, the reduc-
tion of SOCS2 did not alter the expression of ERK at the
basal states (Figure 4b). In contrast to SOCS2 overexpression,
gene silencing of SOCS2 significantly enhanced IGF-1-
induced mesangial cell proliferation, as measured by BrdU
incorporation compared to control cells infected with adv-
GFP by 40% (n¼ 6, Po0.05; Figure 4c).
Effect of SOCS isoforms on the intracellular signaling
pathway of IGF-1
Although SOCS2 overexpression completely inhibited IGF-1-
induced phosphorylation of ERK1/2 (Figure 5), this action is
specific to SOCS2 because overexpression of SOCS1/3
isoforms respectively failed to inhibit ERK1/2 phosphoryla-
tion in mesangial cells induced by IGF-1 (Figure 5). IGF-1
can also activate phosphatidylinositol 3 (PI3) kinase/Akt
pathway, however this pathway is not regulated by SOCS
because overexpression of SOCS1–3 isoforms did not change
the phosphorylation of Akt, a surrogate marker for the PI3
kinase/Akt pathway, with or without IGF-1 (data not shown).
Shc has been reported as one of IGF-1R’s substrates and is
upstream to ERK phosphorylation and activation.18 In
mesangial cells, Shc phosphorylation at Tyr239/240/317 was
not changed at basal states without the addition of IGF-1 to
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Figure 3 | Overexpression of SOCS2 in cultured mesangial cells
suppressed IGF-1-induced collagen IV synthesis and cellular
proliferation. (a) Exogenous SOCS2 was introduced into
mesangial cells using adenoviral vectors containing SOCS2
cDNA-tagged with HA. Immunoblotting displayed the presence of
SOCS2 and HA protein in mesangial cells. (b) Transduction of
adenoviral vector containing SOCS2 (MOI¼ 400) inhibited
IGF-1-induced BrdU incorporation (n¼ 3–6, mean±s.d., *Po0.05
versus IGF-1/GFP 400). Mesangial cells were infected with SOCS2
or GFP expressing adenovirus, incubated with IGF-1 (50 nM) for 16
hrs, and assayed for incorporation of BrdU. (c) mRNA expression of
collagen IV detected by northern blotting analysis in mesangial
cells infected with SOCS2 adenoviral vectors with or without 50 nM
IGF-1 for 6 h. Expression of collagen IV was normalized to 36B4
mRNA and quantified in the lower panel (n¼ 4, mean±s.d.,
*Po0.05).
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signaling in mesangial cells. (a) SOCS2 RNAi decreased SOCS2
protein expression in cultured mesangial cells but did not
changed the expression of SOCS1 and SOCS3 isoforms. Cells were
transfected with SOCS2 RNAi and infected with SOCS2-adenovirus
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(b) Downregulation of SOCS2 enhanced IGF-1-stimulated
phosphorylation of ERK1/2. (c) SOCS2 RNAi increased
IGF-1-induced BrdU incorporation in GFP (left) or SOCS2 (right)
adenoviral infected cells (n¼ 6, Po0.05 comparing IGF-1-treated
cells with or without the transfection of SOCS2siRNA).
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cells infected with ad-GFP or SOCS2-HA-GFP. However,
addition of 50 nM IGF-1 for 5 min increased p66Shc
phosphorylation at Tyr317 (n¼ 5, Po0.05) in GFP adeno-
viral vector-infected mesangial cells but the phosphorylation
of Tyr239/240 site was unchanged (n¼ 5, nonstatistical
significant; Figure 6a and b). Interestingly, overexpression
of SOCS2 (multiplicity of infection¼ 400) reduced IGF-1-
induced phosphorylation of Tyr317 of p66Shc to basal states
(n¼ 4, Po0.05 versus IGF-1-stimulated GFP-infected cells,
nonstatistical versus GFP or SOCS2-infected mesangial cells).
We have also evaluated tyrosine phosphorylation at 239/240/
317 sites of p52Shc. Western blotting revealed SOCS2
overexpression did not alter the basal expression of Tyr239/
240/317 in mesangial cells, nor did it affect IGF-1’s action on
these residues (Figure 6a and b). This study suggests that
phosphorylation of p66Shc at Tyr317, but not Tyr239/240 is
relevant to the downstream effects of IGF-1 in mesangial
cells. In addition, this conclusion is further supported by
studies downregulating SOCS2 expression using RNAi. We
have shown a significant induction of phosphorylation of
p66Shc at Tyr317 that was partially inhibited by the
overexpression of SOCS2 (Supplementary Figure 3).
Direct interaction between SOCS2 and IGF-1 receptor
The potential association of SOCS2 with the IGF-1 receptor
to mediate its actions was characterized in mesangial cells
overexpressing SOCS2. Direct interaction between SOCS2
and IGF-1Rb was determined by co-immunoprecipitation
studies. Cell lysate of mesangial cells infected either with
adenoviral GFP or adv-SOCS2-HA-GFP were immunopreci-
pitated using SOCS2 antibody. The resultant immunopreci-
pitates were analyzed further by immunoblot analysis using
antibodies against HA, revealing the presence of exogenously
expressed SOCS2 protein at 26 kDa in SOCS2-infected cells
with or without IGF-1 but not in control cells. Interestingly,
antibodies to IGF-1Rb did not detect a significant signal in
the immunoprecipitants without the addition of IGF-1.
However, IGF-1Rb subunit was clearly detected in SOCS2-
infected cells following the addition of 50 nM IGF-1
(Figure 7). The interaction between SOCS2 and IGF-1Rb
was further confirmed by immunoprecipitation with anti-
body against IGF-1Rb and then immunoblotted with HA
antibody. Similarly, a strong signal was detected in the
immunoprecipitant from SOCS2-overexpressing mesangial
cells treated with IGF-1 whereas a much weaker signal in
SOCS2-infected cells without IGF-1 (Figure 7). Control cells
infected with viruses containing GFP did not show the
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presence of HA-tagged SOCS2 (Figure 7). These data clearly
demonstrate that SOCS2 and IGF-1Rb are part of the same
protein complex in the presence of IGF-1 in mesangial cells.
Effect of SOCS1, 2, and 3 on insulin’s signal and effects in
mesangial cells
As insulin and IGF-1 share extensive similarities in cellular
actions,19 and insulin has also been known to induce cellular
DNA synthesis, we investigated the effects of SOCS proteins
on insulin’s action on mesangial cells. Insulin (100 nM) was
also able to increase BrdU incorporation by 1.5-fold in
mesangial cells (n¼ 4–7, Po0.05 versus insulin treatment),
but overexpression of SOCS1–3 isoforms failed to alter this
effect of insulin on mesangial cells (n¼ 4–7, Po0.05; Figure
8a). Similarly, overexpression of SOCS1–3 did not have effect
on insulin-induced phosphorylation of ERK1/2 (Figure 8b).
However, insulin-induced Akt phosphorylations were
significantly inhibited by approximately 50% following the
overexpression of SOCS1 and 3 (n¼ 3–6, Po0.05; Figure 8c).
Overexpression of SOCS2 protein, on the contrary, did not
have any effect on insulin’s activation on PI3 kinase/Akt
pathway (Figure 8c).
Insulin induced expression of SOCS2 through STAT5
Putative mechanisms underlying the reduced SOCS2 expres-
sion in the glomeruli in diabetic states were also explored.
STAT5 has been reported to regulate SOCS2 expression in
skeletal muscle cells.20 Microarray analysis revealed a
concomitant reduction of mRNA expression of STAT5 by
twofold in diabetic glomeruli that were normalized by ICT
(Figure 9a). Immunoblot analysis revealed an approximately
30% reduction of STAT5a expression that can be normalized
by insulin treatment, confirming the finding at mRNA level
in the glomerular tissues (Figure 9b). Interestingly, cultured
mesangial cells exposed to media containing 27.8 mM D-
glucose for 3 days showed no change in the protein
expression of STAT5 (Figure 9c). To determine whether
insulin can directly regulate STAT5, expression of STAT5
proteins was studied in cultured mesangial cells exposed to
100 nM of insulin. STAT5 expression was increased by 49%
(n¼ 5, Po0.05) in the presence of insulin in media
containing either 5.6 or 27.8 mM of glucose. (Figure 9c).
DISCUSSION
Numerous studies have reported on the biochemical
mechanisms by which elevated glucose levels cause molecular
and functional abnormalities in renal and vascular cells in
diabetes.21 However, very few studies have assessed the
cellular consequences of insulin deficiency or inhibition of
insulin’s action on the metabolism, function, and prolifera-
tion of renal vascular and glomerular cells. Intervention with
intensive insulin treatment or islet cell transplant can clearly
prevent or may even reverse renal pathologies in diabetic
states.6,22,23 Multiple lines of evidence supported potentially
an important role for insulin in the regulation of renal
functions such as on Naþ /Kþ ATPases in tubular cells.24 In
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Figure 8 | Effects of overexpression of SOCS2 on insulin’s
action on mesangial cells. (a) Overexpression of all SOCS
isoforms did not alter the effect of insulin on BrdU incorporation.
(b) Overexpression of SOCS1–3 isoforms did not changed insulin-
induced phosphorylation of ERK1/2. (c) Overexpression of SOCS1
and 3, but not SOCS2 isoforms inhibited Akt phosphorylation by
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Kidney International (2008) 74, 1434–1443 1439
K Isshiki et al.: SOCS2 and IGF-1 in diabetic nephropathy o r i g i n a l a r t i c l e
this study, we have provided evidence showing that insulin
has important direct effects on the alteration of expression
profile in glomeruli and mesangial cells. Further, the current
study has also identified a new pathway by which the IGF-1
signaling can be inhibited by insulin through its actions on
SOCS2 expression and IGF-1R/Shc complex in the renal
glomeruli.
These results showed for the first time that diabetic rats
had decreased expression of SOCS2 in the glomerular tissues.
This is unlikely due to a direct action of hyperglycemia alone
because mesangial cells cultured in media containing 27.8 mM
glucose did not change SOCS2 or STAT5 expression. Our
data indicated that insulin has a direct effect on SOCS2
expression in mesangial cells. Previously, Sadowski et al.20 has
reported that insulin increased the expression of both SOCS2
and 3 isoforms in C2C12 skeletal muscle cell line. However,
our results indicated that insulin’s regulatory effect on SOCS
expression is isoform specific in mesangial cells because the
expressions of SOCS1 and 3 isoforms were not changed by
insulin. These results therefore suggested a specific action of
SOCS2 in mediating insulin’s biological responses in
mesangial cells. Interestingly, normalization of glucose by
ICT versus insulin pellet appears to have different effects on
the expression of IGF-1R. The reason for this difference is not
known but hyperinsulinemia is more likely associated with
insulin pellet than those received ICT treatment in the renal
capsule.
It has been previously shown that SOCS2 can interact with
IGF-1 receptor in cultured cells overexpressing IGF-1
receptor following the addition of IGF-1 to the culture.13
However, this effect is not known in renal tissues such as
mesangial cells and the downstream biological effects of this
interaction were not reported.13 SOCS2 null mice exhibited
gigantism phenotype with enlargement of most internal
organs.14 They also showed a dramatic increase in the
accumulation of collagen I in intestinal myofibroblasts
following IGF-1 infusion as compared to wild-type control
mice.25 We have clearly demonstrated that downregulation of
SOCS2 in mesangial cells in diabetic states led to increased
actions of IGF-1 on ECM protein production and DNA
synthesis, phenotypes that are present in the progression of
diabetic nephropathy. The effects of IGF-1 on DNA synthesis
and type IV collagen are not large. However, their effects can
be physiologically significant because changes in diabetic
nephropathy require months or even years to develop. Thus,
a change of 30% in the matrix protein levels, with such a slow
turnover rate can be very significant. Furthermore, we have
characterized a potential signaling pathway that confers this
regulation. Following the activation of IGF-1R, transpho-
sphorylation will recruit insulin receptor substrate proteins as
well as other intracellular signaling molecules such as Grb2,
Nck, and Shc.26 This will in turn activate PI3 kinase/Akt and
Ras/Raf-1/MEK/ERK1/2 signaling cascades to elicit down-
stream biological actions such as gene expression, DNA
synthesis and the blockage of cellular apoptosis.19 Activation
of Ras/Raf-1/MEK/ERK1/2 pathway has been well documented
to be essential for the regulation of gene transcription and
DNA synthesis following the phosphorylation of IGF-1R.19
We have shown that SOCS2 protein can suppress the IGF-1-
induced activation of ERK1/2 and therefore provide a
molecular explanation for the inhibitory effect of SOCS2
on IGF-1. This inhibition is pathway-specific because SOCS2
did not inhibit IGF-1’s action on PI3K/Akt pathway. In
addition, the inhibitory effects of SOCS2 on IGF-1’s actions
were also isoform specific. Interestingly, although insulin and
IGF-1 receptor share extensive homology and IGF-1 can bind
to and activate insulin receptor at nonphysiological concen-
trations,19 SOCS2 did not have an effect on insulin’s
activation of MEK/ERK1/2 pathway, suggesting that SOCS2
action to inhibit IGF-1’s action is ligand specific. Further-
more, SOCS2 overexpression can suppress the phosphoryla-
tion of Tyr317 of p66Shc by IGF-1 whereas this inhibition
can be reversed by gene silencing of SOCS2, suggesting that
the inhibition of ERK1/2 pathway is at the level close to IGF-
1R because p66Shc is known to interact with IGF-1R
directly.27 It is possible that SOCS2 can interrupt the binding
of p66Shc to IGF-1R and block the downstream events, and
this possibility requires further investigation. Further, SOCS2
can even enhance cytokine signaling because studies have
shown that SOCS2 can bind to SOCS3 to enhance its
degradation, thus by decreasing SOCS3 levels, SOCS2 can
enhance the signaling of cytokines such as interleukin2 and
interleukin3.28 Nevertheless, we have demonstrated a new
inhibitory mechanism by which insulin can suppress IGF-1/
IGF-1R/Shc/ERK1/2 pathway via SOCS2 protein and the
subsequent reduced gene expression of type IV collagen and
DNA synthesis. It is interesting to note that the over-
expression of SOCS2 in mesangial cells did not significantly
reduce basal DNA synthesis, but only during IGF-1
stimulations, supporting that the effects of SOCS2 is limited
to IGF-1.
A great deal of previous studies have shown that lack of
SOCS2’s inhibitory action could lead to the uncontrolled
cellular proliferation in multiple organs including bone,
heart, liver, and kidney.14,29 We have reported here that the
expression of SOCS2 but not SOCS1/3 is decreased in the
glomeruli of diabetic rats, thus providing the very first
evidence suggesting that the reduced SOCS2 protein expres-
sion may be responsible for nephromegaly in diabetic states.
Further studies using diabetic SOCS2-null mice are required
to establish a definitive role of SOCS2 in diabetic glomerulo-
pathy. The mechanisms of SOCS2 downregulation by
diabetes are likely due to either insulin deficiency or
resistance. We have shown here for the first time that insulin
can increase SOCS2 expression in the mesangial cells and in
the glomeruli. In insulin deficient state, expression of both
STAT5 and SOCS2 were decreased at mRNA and protein
levels, which were normalized by ICT or insulin treatment. In
cultured mesangial cells, insulin directly increased the
expression of SOCS2 without affecting the expression of
SOCS1 and 3. The concomitant downregulation of STAT5
induced by diabetes is likely the cause for the reduction of
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SOCS2 because this protein has been shown to regulate the
expression and action of SOCS2.30 Further studies are needed
to clarify how insulin regulates STAT5 level and whether this
change will decrease SOCS2 expression. The isoform-specific
effect of insulin to increase SOCS2 is important because a
general action to increase SOCS1–5 will result in the
inhibition of insulin’s own actions. Our data have provided
the interesting finding that insulin may have inhibitory effect
on IGF-1’s actions through a STAT5/SOCS2-dependent
pathway. This is very unusual because IGF-1 can generally
enhance the action of insulin. However, our observation
provided evidence for the first time that insulin may also
inhibit IGF-1’s action at postreceptor levels. This could be
highly significant because these data provide a mechanism to
explain the enhanced actions of IGF-1 in mesangial cells
observed in diabetic or obese states, even though most studies
have not observed an increase in IGF-1 expression. In
addition, these results have suggested a novel idea that insulin
can inhibit IGF-1’s cellular actions in cells at physiological
conditions. The pathological significance of these findings for
diabetic nephropathy needs to be evaluated directly because
plasma IGF-1 levels are generally decreased in diabetic states
associated with very poor glycemic control31 and probably
not changed in the renal parenchyma. Our results suggest
that IGF-1’s action in the renal cells can be enhanced due to
loss of insulin’s inhibitory effects and the increased expres-
sion of IGF-1 receptor even without obvious increased levels
of IGF-1. In addition, it is interesting to note that IGF-1’s
contribution on glomerular enlargement and nephropathy in
obesity could be the results of decreases in the inhibitory
actions of insulin on STAT5/SOCS2. Further studies on the
changes in STAT5/SOCS2 in animal models of obesity are in
progress. These data also showed that SOCS isoforms
inhibited insulin and IGF-1’s signaling very differently, with
PI3K/Akt pathway being inhibited with insulin and Shc/
ERK1/2 pathway affected when activated by IGF-1. This
finding may also be extrapolated into other animal model of
diabetes. It has been previously reported that action of IGF-
1R’s pathway was increased in mesangial cells isolated from
NOD mice, possibly due to increases in autocrine expression
of IGF-1.32 This may also be due to the reduced SOCS2
expression.
In summary, we have shown that insulin inhibited IGF-1’s
action by inducing the expression of STAT5 and SOCS2 to
inhibit IGF-1 and IGF-1R activation of ERK pathway. This
action apparently involves the tyrosine phosphorylation of
Tyr317 of p66Sch to reduce the expression of type IV collagen
and mesangial proliferation. In insulin deficiency or diabetic
states, IGF-1’s actions on glomerular cells are significantly
enhanced by the loss of inhibitors actions due to reduction of
STAT5 and SOCS2 and the reduced expression of IGF-1R.
These data have provided new understanding on the
regulatory effects of insulin on IGF-1’s actions and a novel
mechanism in addition to hyperglycemia, by which diabetes
can cause mitogenic actions in glomerular mesangial cells and
also glomerular dysfunctions and pathologies in diabetic rats.
MATERIALS AND METHODS
Materials
Anti-SOCS2, anti-IGF-1Rb, anti-ERK1, anti-HA, anti-SOCS1, anti-
SOCS3, anti-Stat5a, and anti-Shc were from Santa Cruz Biotechno-
logy (Santa Cruz, CA, USA). In part of the experiments, antibody
against SOCS2 was from Abcam (Cambridge, MA). Anti-phospho
MAPK p42/44, anti-phospho Akt, anti-Akt, anti-phospho Shc (Tyr
239/240), and anti-phospho Shc (Tyr 317) were from Cell Signaling
Inc. (Beverly, MA, USA). Human SOCS2 construct and adenoviral
vectors containing HA-tagged human SOCS2, SOCS1, and SOCS3 -
GFP fusion genes were generously provided by Dr Jung-Song Lee
and Dr Steve Shoelson in Joslin Diabetes Center. Recombinant
human IGF-1 was purchased from Calbiochem (San Diego, CA,
USA). LITMUS 28i vector was from New England BioLabs Inc.
(Beverly, MA). Dicer siRNA Generation Kit was from Gene Therapy
System Inc. (San Diego, CA, USA).
Animals and in vivo procedures
Diabetes was induced in male Lewis rats (100–120 g) by single
intraperitoneal injection of STZ (75–90 mg/kg body weight) in 0.1 M
citrate buffer (pH 4.5). The levels of blood glucose were measured 2
days after STZ injection and rats with blood glucose over 250 mg/
100 ml) were used as diabetic rats. In diabetic rats, insulin
(2–3 units) were injected everyday subcutaneously in order to
maintain weight gain and prevent dehydration and ketoacidosis due
to severe hyperglycemia and insulin deficiency. Four weeks after STZ
injection, rats were randomly divided to three experimental groups:
control rats (CTR), diabetic rats without treatment (STZ), diabetic
rats treated with ICT. For ICT, the isolation of islet cells from donor
rats were performed at the day before the transplantation. About
3000 islets isolated from the pancreas of three rats were transplanted
under the capsule of the left kidney of a recipient rat.33 All rats were
allowed free access to food and water. Four weeks after starting
treatment and eight weeks after the initiation of the study, renal
glomeruli were isolated from rats by sieving method as described
previously.34 All procedures were done in accordance with guide-
lines set by Joslin Institutional Animal Care and Use Committee.
Physiological study
GFR and renal plasma flow were measured using a protocol we have
previously established.35 Briefly, inulin (0.6%) and PAH (1.5%) in
saline were infused via a catheter surgically placed in the left jugular
vein of the anesthetized rats at a rate of 6.0 ml/h for 30 min, followed
by a sustained infusion of 2.0 ml/h throughout the experiment. After
60 min, two clearance studies (each 30 min) were performed by
measuring the concentrations of inulin and PAH in both the urine
and blood samples collected from the rats. GFR and renal plasma
flow were determined by inulin and PAH clearance, respectively, and
the filtration fraction was calculated from the ratio of GFR to renal
plasma flow.
Microarray
Total RNA was prepared from isolated glomeruli from four kidneys
of two rats in same group using TRI reagent (Molecular Research
Center Inc., Cincinnati, OH). Complementary DNA synthesis and
cRNA labeling reaction were performed according to Affymetrix
GeneChip Expression Technical Manual and hybridization to the
Rat U34A GeneChip (Affymetrix, Santa Clara, CA). Hybridization
and gene chip expression analysis were performed at Joslin
Diabetes Center Affymetrix DNA microarray Core (DERC, Boston,
MA, USA).
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Cell culture
Mesangial cells were cultured from glomeruli isolated from male
Sprague–Dawley rats (B150 g). The cells were grown in Dulbecco’s
modified Eagle’s medium (glucose 5.6 mM) containing 20% fetal
bovine serum. Cultured cells were identified as mesangial cells using
a previously established criteria.34 Cells were used between second to
seventh passages.
Adenovirus infection
Determination of viral titer and multiplicity of infection for
mesangial cells has been described in figure legends for each
experiment.
RT–PCR
To verify the microarray results, RT–PCR using total RNA from
glomeruli and immunoblot analysis in glomeruli and mesangial cells
were performed. RT–PCR for SOCS2, IGF-1Rb, and GAPDH as
control were performed using standard protocols as previously
described.36 The primer sequences for SOCS2 were sense
50-GAGCTCAGTCAAACAGGATGGTACT-30, antisense 50-AGAAT
CCAATCTGAATTTCCC-30. For IGF-1Rb: sense 50-CAACGACTAT
CAGCAGCTGA-30, antisense 50-TGGTGGAGAGGTAACAGA-30.
For GAPDH: sense 50-GGTGAAGGTCGGTGTCAACGGATT-30,
antisense 50-GATGCCAAAGTTGTCATGGATGACC-30.
Protein isolation and immunoblotting
Homogenized glomeruli and cells were dissolved in lysis buffer
(10 mM Tris-HCl at pH 7.5, 100 mM sodium chloride, 1% NP-40, 1%
Triton X, 50 mM sodium fluoride, 2 mM EDTA, 1 mM pheyl
methylsulphonyl fluoride, 10 mg/ml leupeptin and aprotinin). Some
samples were immunoprecipitated with the indicated antibodies and
protein A/G-Sepharose beads. SDS-polyacrylamide gel electrophor-
esis was performed on 10 or 12% Tris-glycine gel. Immunoblot
analyses were identified with enhanced chemiluminscence
(Amersham, Buckinghamshire, UK).
Northern blot analysis
Total RNA was prepared from mesangial cells using TRI reagent and
northern analysis was performed as previously described.34
BrdU-incorporation assay
Cells were cultured in 96-well plates to B70% confluence infected
with or without SOCS2-adenovirus or transfected with or without
siRNA of SOCS2 and starved for 24 h. Recombinant IGF-1 was then
added at the indicated concentration to cells for 16 h. The BrdU-
incorporation assay was performed using the manufacturer’s specifi-
cations (Roche, Nutley, NJ, USA) with an incorporation time of 2 h.
RNA interference
HA-tagged human SOCS2 cDNA were ligated to LITMUS 28i vector
(New England BioLabs Inc.) and amplified by PCR using T7 primer.
dsRNA synthesis and RNAi generation reaction were performed
according manufacturer’s specifications of Dicer RNAi Generation
Kit (Gene Therapy System Inc.). Mesangial cells were plated at
1 105cells per well in a 24-well plate for immunoblot analysis and
at 1 104 cells per well in a 96-well plate for BrdU incorporation
assay. Twelve hour after plating, mesangial cells were transfected
with 100–500 ng of RNAi with or without indicated constructs using
GeneSilencer siRNA Transfection Reagent (Gene Therapy System
Inc.). One day after transfection, some cells were infected with
HA-tagged SOCS2-adenovirus. The level of SOCS2 was determined
by immunoblotting with anti-SOCS2 antibody and anti-HA anti-
body.
Statistical analysis
Data are expressed as mean±s.d. Comparisons between two groups
were analyzed by Student’s t-test. Comparisons among three or
more groups were analyzed by one-way analysis of variance,
followed by either Scheffe’s test or Bonferroni/Dunn’s multiple
comparison test to evaluate statistical difference between two
groups. P-values less than 0.05 were considered significant.
DISCLOSURE
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work is supported by a grant from National Institute of Health
(DK53105) to GLK, and DK36836 (Joslin’s Diabetes and Endocrinology
Research Center Grant). KI and YY are recipients of American Diabetes
Association mentor-based fellowship. ZH is a recipient of Juvenile
Diabetes Research Foundation fellowship.
SUPPLEMENTARY MATERIAL
Figure S1. Effects of islet cell transplantation (ICT) on the plasma
blood glucose (A) and body weight (B) in diabetic rats.
Figure S2. Expression of SOCS2 protein glomerular tissues isolated
from control rats or rats with 8 weeks of diabetes with or without ICT
treatment for 4 weeks.
Figure S3. The inhibitory effect of SOCS2 on IGF-1-induced Tyr317
phosphorylation of p66Shc was rescued by transfection of RNAi
targeting to SOCS2.
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expression was changed by diabetes and normalized by islet cell
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